DCMD
MCID: MCL027
MIFTS: 50

Macular Dystrophy, Dominant Cystoid (DCMD)

Categories: Eye diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Macular Dystrophy, Dominant Cystoid

MalaCards integrated aliases for Macular Dystrophy, Dominant Cystoid:

Name: Macular Dystrophy, Dominant Cystoid 58 13
Cystoid Macular Edema 12 6 15
Autosomal Dominant Cystoid Macular Edema 60 74
Cystoid Macular Dystrophy 58 60
Macular Edema, Cystoid 58 74
Dcmd 58 60
Cystoid Macular Dystrophy; Cymd 58
Familial Macular Edema 60
Macular Retinal Edema 74
Macular Edema 45
Cymd 58
Mddc 58

Characteristics:

Orphanet epidemiological data:

60
cystoid macular dystrophy
Inheritance: Autosomal dominant; Prevalence: <1/1000000 (Worldwide); Age of onset: Childhood;

OMIM:

58
Inheritance:
autosomal dominant (7p21-p15)


HPO:

33
macular dystrophy, dominant cystoid:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 60  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:4447
OMIM 58 153880
MeSH 45 D008269
NCIt 51 C34794
ICD10 via Orphanet 35 H35.5
Orphanet 60 ORPHA75381
MedGen 43 C0024440

Summaries for Macular Dystrophy, Dominant Cystoid

OMIM : 58 Dominant cystoid macular dystrophy (DCMD) is a progressive retinal dystrophy characterized primarily by early-onset cystoid fluid collections in the neuroretina (summary by Saksens et al., 2015). (153880)

MalaCards based summary : Macular Dystrophy, Dominant Cystoid, also known as cystoid macular edema, is related to retinal vein occlusion and central retinal vein occlusion, and has symptoms including edema and peau d'orange. An important gene associated with Macular Dystrophy, Dominant Cystoid is CYMD (Cystoid Macular Dystrophy). The drugs Bevacizumab and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are edema and strabismus

Related Diseases for Macular Dystrophy, Dominant Cystoid

Diseases related to Macular Dystrophy, Dominant Cystoid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 193)
# Related Disease Score Top Affiliating Genes
1 retinal vein occlusion 31.4 SERPINF1 VEGFA
2 central retinal vein occlusion 31.1 SERPINF1 VEGFA
3 retinal detachment 30.8 CAPN5 SERPINF1 VEGFA
4 macular holes 30.7 KCNMA1 SERPINF1 VEGFA
5 vitreous detachment 30.6 KCNMA1 VEGFA
6 microvascular complications of diabetes 5 30.6 PRKCB SERPINF1 VEGFA
7 macular retinal edema 30.6 BEST1 CAPN5 KCNMA1 MAK MRAP PDE6A
8 optic disk drusen 30.4 KCNMA1 VEGFA
9 endophthalmitis 30.3 MRAP VEGFA
10 diabetic macular edema 30.1 PRKCB SERPINF1 VEGFA
11 diabetic cataract 30.0 SERPINF1 VEGFA
12 retinal vascular disease 29.9 SERPINF1 VEGFA
13 eales disease 29.9 SERPINF1 VEGFA
14 macular degeneration, age-related, 1 29.7 BEST1 KCNMA1 SERPINF1 VEGFA
15 retinitis pigmentosa 28.9 BEST1 CAPN5 MAK PDE6A SERPINF1
16 vitreoretinopathy, neovascular inflammatory 11.7
17 bestrophinopathy 11.6
18 vitreoretinochoroidopathy 11.4
19 cone-rod dystrophy and hearing loss 2 11.1
20 retinitis pigmentosa 83 11.1
21 cytomegalovirus retinitis 10.5
22 microvascular complications of diabetes 1 10.5
23 microvascular complications of diabetes 2 10.5
24 gyrate atrophy of choroid and retina 10.5
25 melanoma 10.4
26 diabetes mellitus 10.4
27 intermediate uveitis 10.4
28 acquired immunodeficiency syndrome 10.4
29 degos 'en cocarde' erythrokeratoderma 10.3
30 ischemia 10.3
31 corneal edema 10.3
32 optic nerve disease 10.3
33 fundus dystrophy 10.3
34 neuropathy 10.3
35 ocular hypertension 10.3
36 central serous chorioretinopathy 10.3
37 retinal microaneurysm 10.2
38 cytokine deficiency 10.2
39 leber congenital amaurosis 4 10.2
40 retinitis 10.2
41 exudative vitreoretinopathy 1 10.2
42 salla disease 10.2
43 birdshot chorioretinopathy 10.2
44 crohn's disease 10.2
45 leukemia 10.2
46 telangiectasis 10.2
47 branch retinal artery occlusion 10.2
48 central retinal artery occlusion 10.2
49 poems syndrome 10.2
50 papilledema 10.2

Graphical network of the top 20 diseases related to Macular Dystrophy, Dominant Cystoid:



Diseases related to Macular Dystrophy, Dominant Cystoid

Symptoms & Phenotypes for Macular Dystrophy, Dominant Cystoid

Human phenotypes related to Macular Dystrophy, Dominant Cystoid:

33 (show all 6)
# Description HPO Frequency HPO Source Accession
1 edema 33 HP:0000969
2 strabismus 33 HP:0000486
3 macular dystrophy 33 HP:0007754
4 hypermetropia 33 HP:0000540
5 cystoid macular edema 33 HP:0011505
6 pericentral retinitis pigmentosa 33 HP:0007947

Symptoms via clinical synopsis from OMIM:

58
Eyes:
strabismus
cystoid macular edema
whitish punctate vitreous deposits
moderate to high hyperopia
diminished visual acuity
more
Radiology:
normal electroretinogram

Clinical features from OMIM:

153880

UMLS symptoms related to Macular Dystrophy, Dominant Cystoid:


edema, peau d'orange

Drugs & Therapeutics for Macular Dystrophy, Dominant Cystoid

Drugs for Macular Dystrophy, Dominant Cystoid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 397)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 124-94-7 31307
3
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 347396-82-1 459903
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
6
Dorzolamide Approved Phase 4,Phase 2 120279-96-1 5284549 3154
7
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
8
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
9
Acetazolamide Approved, Vet_approved Phase 4,Phase 2 59-66-5 1986
10
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3 302-25-0
11
Loteprednol Approved, Experimental Phase 4,Not Applicable 82034-46-6, 129260-79-3 9865442 444025
12
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3 2921-57-5
13
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-24-8 5755
14
Besifloxacin Approved Phase 4 141388-76-3
15
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 83-43-2 6741
16
Linagliptin Approved Phase 4 668270-12-0 10096344
17
Povidone-iodine Approved Phase 4,Phase 3,Not Applicable 25655-41-8
18
Diclofenac Approved, Vet_approved Phase 4,Phase 1,Not Applicable 15307-86-5 3033
19
Nepafenac Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 78281-72-8 151075
20
Methotrexate Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1959-05-2, 59-05-2 126941
21
Timolol Approved Phase 4,Phase 2,Not Applicable 26839-75-8 5478 33624
22
Temazepam Approved, Investigational Phase 4,Phase 3,Not Applicable 846-50-4 5391
23
Verteporfin Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 129497-78-5
24
Azathioprine Approved Phase 4,Phase 3,Phase 2 446-86-6 2265
25
Infliximab Approved Phase 4,Phase 3,Phase 1,Phase 2 170277-31-3
26
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
27
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
28
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 67-73-2 6215
29
Difluprednate Approved Phase 4 23674-86-4 443936
30
Fluprednisolone Approved Phase 4 53-34-9
31
Ketorolac Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 74103-06-3, 66635-83-4 3826
32
Betamethasone Approved, Vet_approved Phase 4,Phase 2,Phase 3 378-44-9 9782
33
Homatropine Approved Phase 4 87-00-3
34
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
35
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
36
tannic acid Approved Phase 4,Phase 2,Phase 3,Phase 1 1401-55-4
37
leucovorin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 58-05-9 143 6006
38
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
39
Glimepiride Approved Phase 4 93479-97-1 3476
40
Empagliflozin Approved Phase 4 864070-44-0
41
Phenylephrine Approved Phase 4 59-42-7 6041
42
Ephedrine Approved Phase 4 299-42-3 9294
43
Pseudoephedrine Approved Phase 4 90-82-4 7028
44
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
45
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
46
Travoprost Approved Phase 4 157283-68-6 5282226
47
Latanoprost Approved, Investigational Phase 4,Phase 2 130209-82-4 5311221 5282380
48
Bimatoprost Approved, Investigational Phase 4,Phase 3,Phase 2 155206-00-1 5311027
49
Dipivefrin Approved Phase 4,Not Applicable 52365-63-6 3105
50
Zinc Approved, Investigational Phase 4 7440-66-6 32051

Interventional clinical trials:

(show top 50) (show all 876)
# Name Status NCT ID Phase Drugs
1 Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO Unknown status NCT00566761 Phase 4 bevacizumab and triamcinolone
2 Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study Unknown status NCT02651168 Phase 4
3 Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema Unknown status NCT02924987 Phase 4 Aflibercept Injection
4 Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy Unknown status NCT01857544 Phase 4 Aflibercept
5 Combination of Standard Lucentis Therapy With Micropulse Diode Laser for the Treatment of Diabetic Macular Edema Unknown status NCT02059772 Phase 4 ranibizumab
6 Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
7 Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis Unknown status NCT03097068 Phase 4 Lucentis
8 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
9 POSTERIOR SUB-TENON'S Avastin Unknown status NCT00567372 Phase 4 bevacizumab (Sub-tenon´s injection)
10 To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema Unknown status NCT02462304 Phase 4 ranibizumab;Bevacizumab
11 Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration Unknown status NCT00716586 Phase 4 dorzolamide
12 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4 bevacizumab;bevacizumab
13 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
14 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
15 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Unknown status NCT02522897 Phase 4 Ranibizumab
16 Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen Unknown status NCT02274259 Phase 4 Aflibercept;Ranibizumab
17 Changes in Macular Thickness After Patterns Scan Laser Unknown status NCT00563628 Phase 4
18 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
19 ALPI vs Medical Therapy Effects on Optic Nerve Structure & Function Unknown status NCT00485238 Phase 4 Intravenous acetazolamide
20 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
21 Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification Unknown status NCT01193504 Phase 4 Pred Forte;Lotemax
22 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
23 Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion Not yet recruiting NCT03709745 Phase 4 Aflibercept Injection [Eylea];Ranibizumab Injection [Lucentis]
24 Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema Completed NCT00682539 Phase 4 Bevacizumab (Avastin);Triamcinolone;Sham
25 Intravitreal Macugen for Ischaemic Diabetic Macular Oedema Completed NCT01175070 Phase 4 Intravitreal injection of pegaptanib sodium
26 Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab Recruiting NCT02665689 Phase 4 ranibizumab
27 Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema Completed NCT02646670 Phase 4 Ranibizumab;Aflibercept;Ranibizumab and Aflibercept;Aflibercept and ranibizumab
28 Fluocinolone Acetonide Insert (ILUVIEN®) for Diabetic Macular Edema (FAD) Study Withdrawn NCT02902744 Phase 4 ILUVIEN®
29 Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema Completed NCT02471651 Phase 4 Dexamethasone intravitreal implant (0.7 mg);Intravitreal anti-VEGF injection
30 Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema. Recruiting NCT03458923 Phase 4 Diclofenac Sodium 0.1 ml containing 500µg;Ranibizumab 0.5 mg Solution for Injection
31 Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular Edema Recruiting NCT02441907 Phase 4 aflibercept
32 Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema Completed NCT02633852 Phase 4 Aflibercept
33 Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision Active, not recruiting NCT01795209 Phase 4 Ranibizumab
34 Macular Edema Nepafenac vs. Difluprednate Uveitis Trial Recruiting NCT01939691 Phase 4 Difluprednate;Nepafenac;Prednisolone acetate
35 Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study) Completed NCT01613716 Phase 4 Ozurdex
36 Laser (Selective Retina Therapy) and Drug Combined Intervention in Clinically Significant Diabetic Macular Edema Active, not recruiting NCT03759860 Phase 4
37 Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema Withdrawn NCT02055911 Phase 4 Ranibizumab
38 Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion Recruiting NCT03405376 Phase 4 Intravitreal aflibercept injection
39 A Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients Completed NCT02359526 Phase 4 IlUVIEN
40 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema Terminated NCT02684084 Phase 4 Ozurdex;Lucentis
41 Topical Nepafenac as Supplement for Diabetic Macular Edema Completed NCT02443012 Phase 4 Topical Gutt Nepafenac 0.1%
42 TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema Completed NCT01870440 Phase 4 Ozurdex Intravitreal Injection (0.7 mg)
43 Aflibercept With and Without Micropulse Laser in Diabetic Macular Edema Completed NCT03866746 Phase 4 Aflibercept Injection
44 Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab Recruiting NCT02559180 Phase 4 aflibercept
45 Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study) Active, not recruiting NCT02788877 Phase 4 aflibercept
46 A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never Treated Not yet recruiting NCT03953807 Phase 4 Dexamethasone Intravitreal Implant
47 Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema Completed NCT00737971 Phase 4 Bevacizumab intravitreal;Triamcinolone;Triamcinolone + Bevacizumab
48 Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema Completed NCT02036424 Phase 4 Ozurdex;Bevacizumab
49 IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab Completed NCT03340610 Phase 4 Alflibercept
50 Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment Completed NCT01257815 Phase 4 Ranibizumab

Search NIH Clinical Center for Macular Dystrophy, Dominant Cystoid

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: macular edema

Genetic Tests for Macular Dystrophy, Dominant Cystoid

Anatomical Context for Macular Dystrophy, Dominant Cystoid

MalaCards organs/tissues related to Macular Dystrophy, Dominant Cystoid:

42
Eye, Endothelial, Retina, Testes, Bone, Myeloid, Kidney

Publications for Macular Dystrophy, Dominant Cystoid

Articles related to Macular Dystrophy, Dominant Cystoid:

(show top 50) (show all 788)
# Title Authors Year
1
Effect of Aflibercept on Cystoid Macular Edema Associated with Central Retinal Vein Occlusion. Results from a District Hospital in the United Kingdom. ( 30795014 )
2019
2
Nonleaking cystoid macular edema in Cohen syndrome. ( 30144585 )
2019
3
CYSTOID MACULAR EDEMA SECONDARY TO RITUXIMAB. ( 28267110 )
2019
4
Risperidone-related bilateral cystoid macular edema: a case report. ( 30862314 )
2019
5
Cystoid Macular Edema With Scattered Intraretinal Hemorrhages in a Persistently Red Eye. ( 30896737 )
2019
6
Risk factors for Cystoid Macular Edema After Descemet Membrane Endothelial Keratoplasty. ( 30973407 )
2019
7
Multimodal OCT Reflectivity Analysis of the Cystoid Spaces in Cystoid Macular Edema. ( 31016197 )
2019
8
Interferon Alpha for Refractory Pseudophakic Cystoid Macular Edema (Irvine-Gass Syndrome). ( 30986123 )
2019
9
Posterior polar annular choroidal dystrophy association with cystoid macular edema. ( 30847215 )
2019
10
Encapsulated metallic intraocular foreign body of long duration presenting with cystoid macular edema and normal full-field electroretinogram. ( 30787536 )
2019
11
The role of Steroids and NSAIDs in prevention and treatment of postsurgical cystoid macular edema. ( 30727876 )
2019
12
Anti-il6-r tocilizumab in refractory and non-infectious uveitic cystoid macular edema. Multicenter study of 25 patients. ( 30660771 )
2019
13
Taxane Induced Cystoid Macular Edema: Case Report and Integrated Pathogenic Theory. ( 30156164 )
2019
14
RESPONSE OF INFLAMMATORY CYSTOID MACULAR EDEMA TO TREATMENT USING ORAL ACETAZOLAMIDE. ( 29346240 )
2019
15
Novel Triamcinolone Acetonide-Loaded Liposomes Topical Formulation for the Treatment of Cystoid Macular Edema After Cataract Surgery: A Pilot Study. ( 30614750 )
2019
16
SARILUMAB FOR RECALCITRANT CYSTOID MACULAR EDEMA IN NON-PARANEOPLASTIC AUTOIMMUNE RETINOPATHY. ( 30986811 )
2019
17
Adalimumab in refractory cystoid macular edema associated with birdshot chorioretinopathy. ( 28608031 )
2018
18
Cystoid macular edema after cataract surgery. ( 30473094 )
2018
19
Prevention of cystoid macular edema after cataract surgery in diabetic patients. ( 30055688 )
2018
20
Randomized controlled European multicenter trial on the prevention of cystoid macular edema after cataract surgery in diabetics: ESCRS PREMED Study Report 2. ( 30055692 )
2018
21
Prevention of cystoid macular edema after cataract surgery. ( 29778103 )
2018
22
European multicenter trial of the prevention of cystoid macular edema after cataract surgery in nondiabetics: ESCRS PREMED study report 1. ( 29778106 )
2018
23
Cystoid Macular Edema in Retinitis Pigmentosa with Intermediate Uveitis Responded Well to Oral and Posterior Subtenon Steroid. ( 28353369 )
2018
24
Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib. ( 30188238 )
2018
25
Is it melanoma-associated retinopathy or drug toxicity? Bilateral cystoid macular edema posing a diagnostic and therapeutic dilemma. ( 29780921 )
2018
26
Cystoid macular edema following selective laser trabeculoplasty in a patient with ocular hypertension. ( 30105491 )
2018
27
Bilateral cystoid macular edema misdiagnosed as pars planitis in a patient on sertraline therapy. ( 29984334 )
2018
28
Incidence and Risk Factors of Cystoid Macular Edema after Vitrectomy with Silicone Oil Tamponade for Retinal Detachment. ( 29022299 )
2018
29
Evaluation of the Effectiveness of Treatment with Dexamethasone Intravitreal Implant in Cystoid Macular Edema Secondary to Retinal Vein Occlusion. ( 30175123 )
2018
30
The Use of Topical Non-steroidal Anti-inflammatory Drugs for Uveitic Cystoid Macular Edema. ( 28080174 )
2018
31
CHANGES IN CHOROIDAL THICKNESS IN CLINICALLY SIGNIFICANT PSEUDOPHAKIC CYSTOID MACULAR EDEMA. ( 28654631 )
2018
32
ACUTE PSEUDOPHAKIC CYSTOID MACULAR EDEMA IMAGED BY OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. ( 28834951 )
2018
33
Letter to the editor regarding: "cystoid macular edema secondary to gyrate atrophy in a child treated with sub-tenon injection of triamcinolone acetonide". ( 30891531 )
2018
34
Incidence of pseudophakic cystoid macular edema in eyes with and without pupil expansion device. ( 30575287 )
2018
35
Cystoid macular edema secondary to gyrate atrophy in a child treated with sub-tenon injection of triamcinolone acetonide. ( 30505995 )
2018
36
EFFECTIVENESS OF EN BLOC REMOVAL OF FIBRINOGEN-RICH COMPONENT OF CYSTOID LESION FOR THE TREATMENT OF CYSTOID MACULAR EDEMA. ( 30334924 )
2018
37
Topical non-steroidal anti-inflammatory drugs for the treatment of cystoid macular edema post Descemet's stripping automated endothelial keratoplasty. ( 30255396 )
2018
38
PREOPERATIVE VITREORETINAL INTERFACE ABNORMALITIES ON SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY AS RISK FACTOR FOR PSEUDOPHAKIC CYSTOID MACULAR EDEMA AFTER PHACOEMULSIFICATION. ( 30157113 )
2018
39
Comparative study of the efficacy and safety of bromfenac, nepafenac and diclofenac sodium for the prevention of cystoid macular edema after phacoemulsification. ( 30046541 )
2018
40
TOPICAL DORZOLAMIDE FOR CYSTOID MACULAR EDEMA IN BIETTI CRYSTALLINE RETINAL DYSTROPHY. ( 30028788 )
2018
41
CYSTOID MACULAR EDEMA IN THE SETTING OF PRIMARY VITREORETINAL LYMPHOMA. ( 30015778 )
2018
42
BILATERAL INTRAVITREAL 0.19-MG FLUOCINOLONE ACETONIDE IMPLANT FOR PERSISTENT NONDIABETIC CYSTOID MACULAR EDEMA AFTER VITRECTOMY. ( 30015770 )
2018
43
Reversible Cystoid Macular Edema Following Uneventful Microinvasive Kahook Dual Blade Goniotomy in a Pseudophakic Patient: A Case Report. ( 29965892 )
2018
44
Cystoid Macular Edema Due to Accidental Latanoprost Overdose After Uncomplicated Phacoemulsification. ( 29921209 )
2018
45
An unexpected complication in bilateral acute iris transillumination: Cystoid macular edema. ( 29786008 )
2018
46
Factors predicting response of pseudophakic cystoid macular edema to topical steroids and nepafenac. ( 29785993 )
2018
47
Effect of topical dorzolamide therapy on cystoid macular edema in hydroxychloroquine retinopathy. ( 29784170 )
2018
48
Metamorphopsia Score and Central Visual Field Outcomes in Diabetic Cystoid Macular Edema. ( 29744359 )
2018
49
Resolution of cystoid macular edema following arginine-restricted diet and vitamin B6 supplementation in a case of gyrate atrophy. ( 29654911 )
2018
50
Prednisolone versus dexamethasone for prevention of pseudophakic cystoid macular edema. ( 29631823 )
2018

Variations for Macular Dystrophy, Dominant Cystoid

ClinVar genetic disease variations for Macular Dystrophy, Dominant Cystoid:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 EYS NM_001142800.1(EYS): c.8519A> G (p.Glu2840Gly) single nucleotide variant Uncertain significance rs1554163965 GRCh37 Chromosome 6, 64431408: 64431408
2 EYS NM_001142800.1(EYS): c.8519A> G (p.Glu2840Gly) single nucleotide variant Uncertain significance rs1554163965 GRCh38 Chromosome 6, 63721512: 63721512

Expression for Macular Dystrophy, Dominant Cystoid

Search GEO for disease gene expression data for Macular Dystrophy, Dominant Cystoid.

Pathways for Macular Dystrophy, Dominant Cystoid

GO Terms for Macular Dystrophy, Dominant Cystoid

Biological processes related to Macular Dystrophy, Dominant Cystoid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 retina development in camera-type eye GO:0060041 8.96 PDE6A SERPINF1
2 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 8.62 PRKCB VEGFA

Sources for Macular Dystrophy, Dominant Cystoid

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....